TELA Bio (NASDAQ:TELA) Issues Earnings Results

Key Points

• TELA Bio reported a quarterly earnings per share (EPS) of ($0.22), which missed the consensus estimate of ($0.18) by $0.04.
• The company has a market capitalization of $73.58 million and a negative return on equity of 402.45%.
• Wall Street Zen downgraded TELA Bio's stock rating from "hold" to "sell," amidst an average target price of $7.25.

TELA Bio (NASDAQ:TELA - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.04), Zacks reports. TELA Bio had a negative net margin of 61.00% and a negative return on equity of 402.45%. TELA Bio updated its FY 2025 guidance to EPS.

TELA Bio Stock Performance

Shares of NASDAQ TELA traded up $0.14 during trading hours on Monday, reaching $1.86. The stock had a trading volume of 227,669 shares, compared to its average volume of 61,297. The firm has a market cap of $73.58 million, a price-to-earnings ratio of -1.32 and a beta of 0.93. The firm has a 50-day moving average of $1.87 and a 200-day moving average of $1.78. The company has a current ratio of 4.22, a quick ratio of 3.40 and a debt-to-equity ratio of 2.28. TELA Bio has a fifty-two week low of $0.86 and a fifty-two week high of $4.08.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded TELA Bio from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, TELA Bio presently has an average rating of "Hold" and an average target price of $7.25.

About TELA Bio

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.